as of 12-09-2025 4:00pm EST
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 203.5M | IPO Year: | 1987 |
| Target Price: | $4.50 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $2.68 | Next Earning Date: | 11-04-2025 |
| Revenue: | $155,097,000 | Revenue Growth: | 12.60% |
| Revenue Growth (this year): | 8.98% | Revenue Growth (next year): | 11.57% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
HRTX Breaking Stock News: Dive into HRTX Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how HRTX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "HRTX Heron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.
